Home » Stocks » ABUS

Arbutus Biopharma Corporation (ABUS)

Stock Price: $3.75 USD -0.06 (-1.57%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $3.80 +0.05 (1.33%) Feb 26, 7:59 PM
Market Cap 317.48M
Revenue (ttm) 6.15M
Net Income (ttm) -83.24M
Shares Out 79.49M
EPS (ttm) -1.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $3.75
Previous Close $3.81
Change ($) -0.06
Change (%) -1.57%
Day's Open 3.94
Day's Range 3.66 - 3.95
Day's Volume 2,415,311
52-Week Range 0.88 - 9.02

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 14 hours ago

Assembly Biosciences Inc (NASDAQ: ASMB) and Arbutus Biopharma Corp (NASDAQ: ABUS) initiated a Phase 2 trial evaluating the former's vebicorvir (VBR), combined with the latter's AB-729 and stan...

GlobeNewsWire - 18 hours ago

Trial will evaluate Assembly's core inhibitor candidate, vebicorvir, with Arbutus' RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapy

Seeking Alpha - 1 month ago

Arbutus Biopharma Corporation is an industry-leading early clinical-stage biopharmaceutical company focused on developing a cure for patients with chronic hepatitis B virus.

GlobeNewsWire - 1 month ago

2021 objectives leverage positive momentum in Arbutus' Hepatitis B research and development programs

GlobeNewsWire - 1 month ago

WARMINSTER, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people wi...

Zacks Investment Research - 2 months ago

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

Zacks Investment Research - 2 months ago

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

GlobeNewsWire - 2 months ago

Repeat dosing of 60 mg AB-729 every 8 weeks resulted in mean HBsAg declines of –1.37 log10 (N=6) comparable to AB-729 dosed every 4 weeks ( –1.44 log10, N=7, p

GlobeNewsWire - 3 months ago

Data released today expands on November 15, 2020 AASLD presentation

GlobeNewsWire - 3 months ago

Across all single-dose cohorts, mean HBsAg concentrations continuously declined up to week 12 before reaching a plateau , suggesting dosing of AB-729 less frequently than every 4 weeks may be ...

Zacks Investment Research - 3 months ago

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

GlobeNewsWire - 3 months ago

WARMINSTER, Penn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people ...

Seeking Alpha - 3 months ago

Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Arbutus (ABUS) delivered earnings and revenue surprises of -35.00% and -15.62%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 3 months ago

Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

WARMINSTER, Pa., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people...

GlobeNewsWire - 5 months ago

Mean HBsAg reduction of 1.23 log10 IU/mL at week 12 with a favorable safety  and tolerability profile 

GlobeNewsWire - 5 months ago

WARMINSTER, Pa., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people...

24/7 Wall Street - 5 months ago

America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic.

Other stocks mentioned: AZN, JNJ, MRNA, NVAX, PFE
GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif. and WARMINSTER, Pa., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) and Arbutus Biopharma Corporation (Nasdaq: ABUS), today announced...

Zacks Investment Research - 6 months ago

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

Zacks Investment Research - 6 months ago

Is (ABUS) Outperforming Other Medical Stocks This Year?

The Motley Fool - 6 months ago

Short-term investors appear impatient.

Seeking Alpha - 6 months ago

Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Arbutus (ABUS) delivered earnings and revenue surprises of -8.70% and -17.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 6 months ago

Shares of Arbutus Biopharma (NASDAQ:ABUS) fell 1% in pre-market trading after the company reported Q2 results.

GlobeNewsWire - 6 months ago

Phase 1a/1b clinical trial for AB-729, a subcutaneously delivered RNAi agent, remains on track with results from additional cohorts expected in the second half of 2020

Seeking Alpha - 6 months ago

The biotech sector in the stock market has been on fire lately.

GlobeNewsWire - 6 months ago

WARMINSTER, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people ...

The Motley Fool - 6 months ago

Here's what drove shares of these healthcare stocks through the roof last month.

Other stocks mentioned: ALT, OMI
Zacks Investment Research - 6 months ago

Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 6 months ago

WARMINSTER, Pa., July 29, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people ...

Zacks Investment Research - 6 months ago

Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 7 months ago

The ruling means Moderna may have to pay royalties on its mRNA-based vaccines -- including its coronavirus candidate.

24/7 Wall Street - 7 months ago

Arbutus Biopharma Corp. (NASDAQ: ABUS) stock has seen an incredible rise over the past few days after the firm won a patent dispute that could have implications for coronavirus vaccine frontru...

24/7 Wall Street - 9 months ago

Arbutus Biopharma Corp. (NASDAQ: ABUS) shares jumped on Tuesday after the company reported positive data from its early stage clinical trial in patients with chronic hepatitis B virus (HBV) in...

GlobeNewsWire - 9 months ago

 Mean 60 mg HBsAg reduction of 0.99 log10 IU/mL at week 12, with normal ALT and AST values throughout the follow-up period

Zacks Investment Research - 9 months ago

Arbutus (ABUS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 9 months ago

As of late, it has definitely been a great time to be an investor in Arbutus Biopharma.

Seeking Alpha - 9 months ago

Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Arbutus Biopharma Corporation (ABUS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Zacks Investment Research - 9 months ago

Arbutus (ABUS) delivered earnings and revenue surprises of 21.88% and -17.62%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 9 months ago

Shares of Arbutus Biopharma (NASDAQ:ABUS) rose 12.6% in pre-market trading after the company reported Q1 results.

Zacks Investment Research - 9 months ago

Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 10 months ago

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

GlobeNewsWire - 11 months ago

Positive single dose AB-729 data in chronic hepatitis B subjects supports  further clinical development

Seeking Alpha - 11 months ago

Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

Arbutus (ABUS) delivered earnings and revenue surprises of 2.70% and 10.34%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 11 months ago

Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

Arbutus expects to announce AB-729 Preliminary Phase 1a/1b Data late Q12020

About ABUS

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-836, a capsid inhibitor that has the potential to inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach t... [Read more...]

Industry
Biotechnology
CEO
William Collier
Employees
78
Stock Exchange
NASDAQ
Ticker Symbol
ABUS
Full Company Profile

Financial Performance

In 2019, ABUS's revenue was $6.01 million, an increase of 1.11% compared to the previous year's $5.95 million. Losses were -$153.72 million, 169.4% more than in 2018.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for ABUS stock is "Buy." The 12-month stock price forecast is 6.71, which is an increase of 78.93% from the latest price.

Price Target
$6.71
(78.93% upside)
Analyst Consensus: Buy